ATLANTA — Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy — a first step therapy designed to reduce cancer cells numbers — with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy. The findings were reported by Craig B. Reeder, M.D., at the American Society of Hematology’s annual meeting.
